AcroCyte wins ARPA-H grant to scale human organoid technology
What's the deal? AcroCyte Therapeutics has been selected to receive a grant from the Advanced Research Projects Agency for Health (ARPA-H)Dealroom has a profile for this one. Try Dealroom → to advance scalable human organoid technologies for regenerative medicine. The company, based in Taipei and San Carlos, California, announced the award on July 23, 2026.
What's the endgame? AcroCyte's proprietary RCE® (Rapid Reproducible Rare Cell 3D Expansion) platform enables reproducible, standardized 3D expansion of rare human cells. It is FDA-registered as a Class I medical device — the first standardized organoid expansion system to hold that designation.
The technology takes autologous kidney cells obtained through minimally invasive procedures and expands them within weeks into renal organoid modules, opening pathways beyond conventional organ transplantation.
Why now? Regenerative medicine is an ARPA-H priority, with flagship programs targeting the global shortage of transplantable organs. Established in 2022 and modeled on DARPA, the agency funds high-risk, high-reward research over incremental advances.
What's the plan? The project runs on a binational strategy across the US and Taiwan. AcroCyte will work with the University of Chicago MedicineDealroom has a profile for this one. Try Dealroom →, National Taiwan University Hospital (NTUH), and the National Center for Biomodels to pursue parallel development and align early with international regulatory standards.
"Being selected for support by ARPA-H is a strong validation of our team's long-term commitment to advancing three-dimensional cell technologies," said Dr. Ying C. Chang, co-founder and chief executive officer of AcroCyte. The company was the first Taiwanese biotech to place second in the MEDICA 2025 Start-up Competition.
"Kidney disease remains a significant health concern in Taiwan," said Professor Jia-Horng Kao, vice superintendent of NTUH, adding that the collaboration aims to integrate global research resources and clinical expertise.
The signal: Human organoids are a promising frontier, but clinical translation has stalled on scalability, reproducibility, and manufacturing standardization. AcroCyte's grant signals institutional confidence that standardized expansion platforms — not just novel biology — are the missing link between the lab and regenerative medicine at scale.
Image credit: Generated with Gemini
